FINHUB Insights

AMGN · Q3 FY25 · Jul 1 – Sep 30, 2025

Amgen Q3 FY25: where the revenue came from and where it went

Amgen Q3 FY25: revenue $9.6B (+12% year over year). Net profit $3.2B. Largest cohort Other $3.5B. The whole income statement as a sankey diagram from the SEC filing.

Period
Jul 1 – Sep 30, 2025
Reported
Nov 5, 2025 10-Q
Sankey diagram of Amgen's income statement for Q3 FY25: revenue of $9.6 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$9.6B +12% year over year
Gross profit$6.5B 68% margin
Operating profit$2.5B 26% margin
Net profit$3.2B 34% margin

The numbers

All figures in billions of U.S. dollars, for Q3 FY25 (period ends Sep 30, 2025).
ItemValueShare of revenueYear over year
Revenue 9.6 100% +12%
Other 3.5 36%
Other Products 1.9 20% +36%
Prolia 1.1 11% +9%
Repathaevolocumab 0.8 8% +40%
Otezla 0.6 6% +4%
Enbrel 0.6 6% −30%
TEPEZZA 0.6 6% +15%
EVENITY 0.5 5% +36%
Cost of revenue−3.132%
Gross profit6.568% margin+7pp
SG&A−1.718%−1pp
Other−2.223%+0pp
Operating profit2.526% margin+2pp
Tax−0.7
Net profit3.234%+0pp
Filing on EDGAR More quarters of AMGN

Source of the numbers: structured XBRL data from the filing (10-Q). The diagram is generated automatically and checked against EDGAR before release. How we calculate it → About and methodology.

Older quarters